JP2008509982A5 - - Google Patents

Download PDF

Info

Publication number
JP2008509982A5
JP2008509982A5 JP2007526578A JP2007526578A JP2008509982A5 JP 2008509982 A5 JP2008509982 A5 JP 2008509982A5 JP 2007526578 A JP2007526578 A JP 2007526578A JP 2007526578 A JP2007526578 A JP 2007526578A JP 2008509982 A5 JP2008509982 A5 JP 2008509982A5
Authority
JP
Japan
Prior art keywords
urea
ureido
ylphenyl
benzoic acid
fluorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2007526578A
Other languages
English (en)
Japanese (ja)
Other versions
JP2008509982A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/GB2005/050131 external-priority patent/WO2006018662A2/en
Publication of JP2008509982A publication Critical patent/JP2008509982A/ja
Publication of JP2008509982A5 publication Critical patent/JP2008509982A5/ja
Pending legal-status Critical Current

Links

JP2007526578A 2004-08-16 2005-08-16 アリール尿素誘導体 Pending JP2008509982A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60226804P 2004-08-16 2004-08-16
PCT/GB2005/050131 WO2006018662A2 (en) 2004-08-16 2005-08-16 Aryl urea derivatives for treating obesity

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2012037806A Division JP2012140445A (ja) 2004-08-16 2012-02-23 アリール尿素誘導体

Publications (2)

Publication Number Publication Date
JP2008509982A JP2008509982A (ja) 2008-04-03
JP2008509982A5 true JP2008509982A5 (enExample) 2008-08-07

Family

ID=35134573

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2007526578A Pending JP2008509982A (ja) 2004-08-16 2005-08-16 アリール尿素誘導体
JP2012037806A Withdrawn JP2012140445A (ja) 2004-08-16 2012-02-23 アリール尿素誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2012037806A Withdrawn JP2012140445A (ja) 2004-08-16 2012-02-23 アリール尿素誘導体

Country Status (4)

Country Link
US (2) US20080261952A1 (enExample)
EP (1) EP1786422A2 (enExample)
JP (2) JP2008509982A (enExample)
WO (1) WO2006018662A2 (enExample)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4198733B2 (ja) 2003-07-22 2008-12-17 アリーナ ファーマシューティカルズ, インコーポレイテッド 関連性障害の予防および処置に有用な、5−ht2aセロトニンレセプターのモジュレーターとしてのジアリールおよびアリールへテロアリールウレア誘導体
WO2005044785A1 (en) 2003-10-30 2005-05-19 Merck & Co., Inc. Aralkyl amines as cannabinoid receptor modulators
EP1727803B3 (en) 2004-03-23 2014-04-23 Arena Pharmaceuticals, Inc. Processes for preparing substituted n-aryl-n'-[3-(1h-pyrazol-5-yl)phenyl] ureas and intermediates thereof
EP1807390A4 (en) * 2004-11-04 2008-07-02 Neurogen Corp ARYL ALKYL UREA AS CB1 ANTAGONISTS
SA05260357B1 (ar) 2004-11-19 2008-09-08 ارينا فارماسيتو تيكالز ، أنك مشتقات 3_فينيل_بيرازول كمعدلات لمستقبل سيروتينين 5_ht2a مفيدة في علاج الاضطرابات المتعلقه به
WO2006062982A2 (en) 2004-12-07 2006-06-15 Locus Pharmaceuticals, Inc. Urea inhibitors of map kinases
CN101253152A (zh) * 2005-09-02 2008-08-27 安斯泰来制药株式会社 作为rock抑制剂的酰胺衍生物
TWI370130B (en) 2005-11-24 2012-08-11 Eisai R&D Man Co Ltd Two cyclic cinnamide compound
TWI378091B (en) 2006-03-09 2012-12-01 Eisai R&D Man Co Ltd Multi-cyclic cinnamide derivatives
AU2007254244C1 (en) 2006-05-18 2014-07-31 Arena Pharmaceuticals, Inc. 3-pyrazolyl-benzamide-4-ethers, secondary amines and derivatives thereof as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
NZ571829A (en) 2006-05-18 2011-10-28 Arena Pharm Inc Crystalline forms and processes for the preparation of phenyl-pyrazoles useful as modulators of the 5-HT2A serotonin receptor
JP5406018B2 (ja) 2006-05-18 2014-02-05 アリーナ ファーマシューティカルズ, インコーポレイテッド 5−ht2aセロトニンレセプターに関連する障害の処置に有用な5−ht2aセロトニンレセプターのモジュレーターとしての1級アミン、およびその誘導体
EP2019093A4 (en) * 2006-05-19 2011-02-23 Eisai R&D Man Co Ltd CINEMA ACID AMID DERIVATIVE FROM THE UREA TYPE
CA2657120A1 (en) * 2006-08-01 2008-02-07 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
JP2010504362A (ja) * 2006-09-25 2010-02-12 アレテ セラピューティクス, インコーポレイテッド 可溶性エポキシドヒドロラーゼ阻害剤
TWI415845B (zh) 2006-10-03 2013-11-21 Arena Pharm Inc 用於治療與5-ht2a血清素受體相關聯病症之作為5-ht2a血清素受體之調節劑的吡唑衍生物
FR2908409B1 (fr) * 2006-11-10 2009-01-09 Sanofi Aventis Sa Pyrazoles substituees,compositions les contenant,procede de fabrication et utilisation
US20080207900A1 (en) 2007-02-28 2008-08-28 Teiji Kimura Two cyclic oxomorphorin derivatives
US9567327B2 (en) 2007-08-15 2017-02-14 Arena Pharmaceuticals, Inc. Imidazo[1,2-a]pyridine derivatives as modulators of the 5-HT2A serotonin receptor useful for the treatment of disorders related thereto
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
US7935815B2 (en) 2007-08-31 2011-05-03 Eisai R&D Management Co., Ltd. Imidazoyl pyridine compounds and salts thereof
TW200916469A (en) 2007-08-31 2009-04-16 Eisai R & Amp D Man Co Ltd Multi-cyclic compounds
WO2009035951A2 (en) * 2007-09-11 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
WO2009035949A2 (en) * 2007-09-13 2009-03-19 Arete Therapeutics, Inc. Soluble epoxide hydrolase inhibitors
US20110021538A1 (en) 2008-04-02 2011-01-27 Arena Pharmaceuticals, Inc. Processes for the preparation of pyrazole derivatives useful as modulators of the 5-ht2a serotonin receptor
WO2010018856A1 (ja) * 2008-08-13 2010-02-18 持田製薬株式会社 カンナビノイド受容体関連疾患の予防/改善または治療剤
JP2012500223A (ja) * 2008-08-15 2012-01-05 ローカス ファーマスーティカルズ,インコーポレイテッド Mapキナーゼインヒビターとしての尿素誘導体
US9126946B2 (en) 2008-10-28 2015-09-08 Arena Pharmaceuticals, Inc. Processes useful for the preparation of 1-[3-(4-bromo-2-methyl-2H-pyrazol-3-yl)-4-methoxy-phenyl]-3-(2,4-difluoro-phenyl)urea and crystalline forms related thereto
CN102264354B (zh) 2008-10-28 2015-03-25 艾尼纳制药公司 用于治疗5-ht2a5-羟色胺受体相关障碍的5-ht2a5-羟色胺受体调节剂组合物
WO2011062955A2 (en) * 2009-11-18 2011-05-26 University Of Massachusetts Compounds for modulating tlr2
WO2011075596A1 (en) 2009-12-18 2011-06-23 Arena Pharmaceuticals, Inc. Crystalline forms of certain 3-phenyl-pyrazole derivatives as modulators of the 5-ht2a serotonin receptor useful for the treatment of disorders related thereto
US9452980B2 (en) 2009-12-22 2016-09-27 Hoffmann-La Roche Inc. Substituted benzamides
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8697739B2 (en) * 2010-07-29 2014-04-15 Novartis Ag Bicyclic acetyl-CoA carboxylase inhibitors and uses thereof
BRPI1004176A2 (pt) * 2010-10-25 2015-08-11 Univ Rio De Janeiro Compostos aril e/ou hetero aril uréias funcionalizados; processo de síntese desses composto; composição farmacêutica contendo tais compostos e usos
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
EP2683699B1 (de) 2011-03-08 2015-06-24 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
US8461179B1 (en) 2012-06-07 2013-06-11 Deciphera Pharmaceuticals, Llc Dihydronaphthyridines and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
ES2489297B1 (es) 2013-01-22 2015-06-10 Consejo Superior De Investigaciones Científicas (Csic) Benzotiazoles sustituidos y sus aplicaciones terapeuticas para el tratamiento de enfermedades humanas
US9926275B2 (en) * 2013-08-22 2018-03-27 Northeastern University Allosteric modulators of the cannabinoid 1 receptor
GB201401886D0 (en) 2014-02-04 2014-03-19 Lytix Biopharma As Neurodegenerative therapies
WO2015162216A1 (en) * 2014-04-24 2015-10-29 Universita' Degli Studi Di Siena Biaryl amide or urea derivatives as trpv1 ligands
CZ305633B6 (cs) * 2014-08-13 2016-01-13 Univerzita Hradec Králové Deriváty benzothiazolylmočoviny, způsob jejich přípravy a jejich použití
EP3201174A4 (en) * 2014-10-03 2018-06-06 The Royal Institution for the Advancement of Learning / McGill University Urea and bis-urea based compounds and analogues thereof useful in the treatment of androgen receptor mediated diseases or disorders
WO2016201373A1 (en) 2015-06-12 2016-12-15 Axovant Sciences Ltd. Diaryl and arylheteroaryl urea derivatives useful for the prophylaxis and treatment of rem sleep behavior disorder
HK1247555A1 (zh) 2015-07-15 2018-09-28 Axovant Sciences Gmbh 用於预防和治疗与神经变性疾病相关的幻觉的作为5-ht2a血清素受体的调节剂的二芳基脲和芳基杂芳基脲衍生物
AU2017228405A1 (en) 2016-03-03 2018-10-18 Cornell University Small molecule IRE1-alpha inhibitors
JP6814814B2 (ja) 2016-03-17 2021-01-20 エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft Taarのアゴニストとしての活性を有する5−エチル−4−メチル−ピラゾール−3−カルボキサミド誘導体
EP3621951A4 (en) * 2017-05-12 2021-01-27 Research Triangle Institute DIARYL URINE AS CB1 ALLOSTERIC MODULATORS
JP2021512105A (ja) 2018-01-31 2021-05-13 デシフェラ・ファーマシューティカルズ,エルエルシー 消化管間質腫瘍の治療のための併用療法
CN118903436A (zh) 2018-01-31 2024-11-08 德西费拉制药有限责任公司 治疗肥大细胞增多症的组合疗法
WO2020126968A2 (en) * 2018-12-20 2020-06-25 Bayer Aktiengesellschaft Urea derivatives
AU2020308862A1 (en) * 2019-06-28 2022-01-20 Research Triangle Institute Urea derivatives as CB1 allosteric modulators
TWI878335B (zh) 2019-08-12 2025-04-01 美商迪賽孚爾製藥有限公司 治療胃腸道基質瘤方法
NZ784949A (en) 2019-08-12 2025-09-26 Deciphera Pharmaceuticals Llc Ripretinib for treating gastrointestinal stromal tumors
SMT202400484T1 (it) 2019-12-30 2025-01-14 Deciphera Pharmaceuticals Llc Composizioni di 1-(4-bromo-5-(1-etil-7-(metilammino)-2-osso-1,2-diidro-1,6-naftiridin-3-il)-2-fluorofenil)-3-fenilurea
FI4084778T3 (fi) 2019-12-30 2023-12-18 Deciphera Pharmaceuticals Llc Amorfisia kinaasi-inhibiittoriformulaatioita ja menetelmiä niiden käyttämiseksi
WO2021222637A1 (en) 2020-04-30 2021-11-04 United States Government As Represented By The Department Of Veterans Affairs Krüppel-like factor 15 (klf15) small molecule agonists in kidney disease
US11779572B1 (en) 2022-09-02 2023-10-10 Deciphera Pharmaceuticals, Llc Methods of treating gastrointestinal stromal tumors
WO2024246857A1 (en) * 2023-06-02 2024-12-05 Innopharmascreen Inc. Urea compounds, compositions, and methods for treating asthma and parkinson's disease
WO2025085745A1 (en) 2023-10-18 2025-04-24 Gen1E Lifesciences Inc. Modulators of extracellular signal-regulated kinase

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4088768A (en) * 1975-05-06 1978-05-09 Eli Lilly And Company N-heterocyclic ureas as immune regulants
DK41193D0 (da) * 1993-04-07 1993-04-07 Neurosearch As Ionkanalaabnere
WO2004048319A1 (en) * 2002-11-25 2004-06-10 7Tm Pharma A/S Novel benzamide compounds for use in mch receptor related disorders
US20090239841A1 (en) * 2004-10-27 2009-09-24 Hutchison Alan J Diaryl Ureas as CB1 Antagonists

Similar Documents

Publication Publication Date Title
JP2008509982A5 (enExample)
RU2348625C2 (ru) Энантиомеры производных тиофенгидроксамовой кислоты и их применение в качестве ингибиторов гдац
RU2492167C2 (ru) Производные аминотриазола в качестве агонистов alх
US20080261952A1 (en) Aryl Urea Derivatives for Treating Obesity
JP2013506637A5 (enExample)
RU2205827C2 (ru) Производное ацилпиперазинилпиримидина, способы его получения, фармацевтическая композиция
JP2007519695A5 (enExample)
JP5015586B2 (ja) Ep4受容体アンタゴニスト
JP2009507080A5 (enExample)
JP2005527625A5 (enExample)
JP2009520686A5 (enExample)
JP2006525298A5 (enExample)
RU2007117913A (ru) 2, 6-замещенные-4-монозамещенный амино-пиримидины как антагонисты рецептора простагландина d2
RU2005137403A (ru) Новые замещенные 3-сера-индолы
RU2017139727A (ru) Гетероциклические ингибиторы erk1 и erk2 и их применение для лечения злокачественного новообразования
JP2009525960A5 (enExample)
RU2009102770A (ru) Производные бензимидазола, методы их получения, применение их в качестве агонистов фарнезоид-х-рецептора (fxr) и содержащие их фармацевтические препараты
CA2454703A1 (en) Novel thiophene carboxamide derivatives
JP2006507241A5 (enExample)
RU2011115111A (ru) Замещенные пирролидин-2-карбоксамиды
RU2005124359A (ru) Пирролилтиазолы и их применение в качестве обратных агонистов рецептора св 1
CN1124488A (zh) 新的噻唑烷二酮及含有这些化合物的药剂
RU2007140737A (ru) Пиразолы
RU2007114125A (ru) Замещенные гидантоины для лечения рака
WO2005026127A1 (ja) プラスミノゲンアクチベータインヒビター-1阻害剤